Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Financial Results: Page 2
Qiagen Q1 net sales decline 23% on COVID headwinds; non-COVID sales rise
By
Leo O'Connor
Non-COVID product group sales rose due to underlying double-digit growth at constant exchange rates in consumables and related revenues.
May 4, 2023
Bio-Techne fiscal Q3 sales rise 1% on strength in cell therapy, prostate test products
By
Leo O'Connor
Among recent business highlights, the firm noted its ExoDx Prostate test increased its addressable market by approximately 50% after receiving expanded Medicare coverage.
May 3, 2023
PacBio Q1 revenue rises 17%
By
LabPulse.com staff writers
The company received its first orders for the Onso short-read sequencing system and released new workflows in collaboration with Corteva Agriscience that enable the sequencing of thousands of plant and microbial genome samples annually.
May 2, 2023
QuidelOrtho Q1 revenues drop with lower respiratory testing
By
LabPulse.com staff writers
On a supplemental combined basis, first-quarter respiratory testing revenues, including COVID-19 testing, fell 72% year-over-year to $265.6 million from $947.3 million. Non-respiratory testing revenues rose 5% year-over-year.
May 3, 2023
Hologic fiscal Q2 diagnostics revenue drops 53%; firm beats analyst estimates
By
Leo O'Connor
Molecular Diagnostics revenue of $342.2 million fell 60% from $862.5 million in the prior year quarter, as COVID-19 testing demand plummeted.
May 1, 2023
Labcorp Q1 revenues drop 3% as base business growth surges
By
Leo O'Connor
Growth in the total Base Business, which excluded COVID-19 testing but included revenues from a lab management agreement with Ascension health system, was 19.8% compared to the Base Business in the prior year.
April 27, 2023
Roche, Thermo Fisher sales drop on diagnostic testing decline in Q1
By
Leo O'Connor
Thermo Fisher’s Life Sciences Solutions revenues declined 38% in Q1 compared to the prior-year quarter, but its Analytical Instruments revenues rose 13%.
April 26, 2023
Abbott Q1 diagnostics sales decline, but CEO sees milder impact from pandemic
By
Leo O'Connor
The impact of COVID-19 on its overall business “has rapidly and significantly lessened,” according to Abbott Chairman and CEO Robert Ford.
April 19, 2023
Oncocyte to lay off 20% of workforce in cost restructuring
By
Leo O'Connor
The CEO said the layoff is part of a plan to bring its cost structure in line with its kitted product strategy and to optimize operational efficiency.
April 13, 2023
SomaLogic CEO steps down; Q4 revenue declines 18%
By
Leo O'Connor
SomaLogic is at a stage where it needs "seasoned leaders to accelerate market adoption," said Troy Cox, executive chairman of the board of directors.
March 29, 2023
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
By
Leo O'Connor
The firm recorded an accounting impairment in Q4 for excess manufacturing and inventory related to the scale-up during peak COVID-19 testing demand and the decision to pause commercialization of its Amira COVID-19 test.
March 21, 2023
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
By
Leo O'Connor
The company’s revenues have come predominantly from its COVID-19 testing product, but it is "executing well" on its strategy of expanding the test menu, CEO Ayub Khattak said.
March 16, 2023
Previous Page
Page 2 of 12
Next Page